AXSM Q3 2017 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$8B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$6M

Net Income

-$6M

EPS (Diluted)

$-0.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$388,045

Balance Sheet

Total Assets

$33M

Total Liabilities

$16M

Stockholders' Equity

$17M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$6M	-$7M	+12.6%
Net Income	-$6M	-$7M	+10.6%